Latest News and Press Releases

Entrada Therapeutics reports financial results for the fourth quarter and full year ended December 31, 2025, and highlights recent business updates.

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com Market Intelligence Brief — WHAT'S HAPPENING: The infrastructure holding the global economy together is being...

WESTPORT, Conn., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI”), an owner of leading middle market businesses, today announced the appointment of Eric Weis as President...

CervoMed's neflamapimod has been selected for the U.K.’s EXPERTS-ALS platform to rapidly evaluate it in ALS

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

MEMPHIS, Tenn. and LOS ANGELES and WILLIAMSBURG, Va., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kemmons Wilson Hospitality Partners (“KWHP”), a hospitality-focused investment management firm, together with...

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to...

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to...

WOODLAND PARK, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced a series of live demonstrations, collaborations, and industry engagements at DISTRIBUTECH 2026, where...